Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ

Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary Shares, which includes shares sold pursuant to a full exercise of the underwriters’ over-allotment option. The ADSs are listed on the NASDAQ Global Select Market under the symbol “ABLX” and Ablynx’s ordinary shares are listed on Euronext Brussels under the symbol “ABLX.”

Headquartered in Belgium, Ablynx is a late-stage clinical biopharmaceutical company engaged in the development of nanobodies to develop treatments for a broad range of therapeutic indications with an unmet medical need. 

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Marcel Fausten, counsel Yasin Keshvargar and associates Rahim Manji, Joshua S. Sills and Carrie Guo. The intellectual property and technology team included counsel David R. Bauer and associates Bonnie Chen and Carrie Guo. The tax team included partner Kathleen L. Ferrell. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.